4.2 Article

Genome-wide Network-assisted Association and Enrichment Study of Amyloid Imaging Phenotype in Alzheimer's Disease

期刊

CURRENT ALZHEIMER RESEARCH
卷 16, 期 13, 页码 1163-1174

出版社

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1567205016666191121142558

关键词

Alzheimer's disease; amyloid imaging phenotype; genome-wide association; network analysis; pathway enrichment; consensus modules; neurodegenerative disease

资金

  1. National Natural Science Foundation of China [61773134, 61803117]
  2. Fundamental Research Funds for the Central Universities [3072019CFM0403, HEUCFG201824]
  3. Natural Science Foundation of Heilongjiang Province of China at Harbin Engineering University [YQ2019F003]
  4. MOE (Ministry of Education in China) Project of Humanities and Social Sciences at the Changzhou Institute of Technology [19YJCZH120]
  5. NIH at the Indiana University [R01 EB022574, R01 LM011360, U01 AG024904, RC2 AG036535, R01 AG19771, P30 AG10133]
  6. University of Pennsylvania
  7. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  8. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  9. National Institute on Aging
  10. National Institute of Biomedical Imaging and Bioengineering
  11. AbbVie
  12. Alzheimer's Association
  13. Alzheimer's Drug Discovery Foundation
  14. Araclon Biotech
  15. BioClinica, Inc.
  16. Biogen
  17. Bristol-Myers Squibb Company
  18. CereSpir, Inc.
  19. Eisai Inc.
  20. Elan Pharmaceuticals, Inc.
  21. Eli Lilly and Company
  22. EuroImmun
  23. F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.
  24. Fujirebio
  25. GE Healthcare
  26. IXICO Ltd.
  27. Janssen Alzheimer Immunotherapy Research AMP
  28. Development, LLC
  29. JohnsonAMP
  30. Johnson Pharmaceutical Research AMP
  31. Development LLC
  32. Lumosity
  33. Lundbeck
  34. Merck Co., Inc.
  35. Meso Scale Diagnostics, LLC
  36. NeuroRx Research
  37. Neurotrack Technologies
  38. Novartis Pharmaceuticals Corporation
  39. Pfizer Inc.
  40. Piramal Imaging
  41. Servier
  42. Takeda Pharmaceutical Company
  43. Transition Therapeutics
  44. Canadian Institutes of Health Research

向作者/读者索取更多资源

Background: The etiology of Alzheimer's disease remains poorly understood at the mechanistic level, and genome-wide network-based genetics have the potential to provide new insights into the disease mechanisms. Objective: The study aimed to explore the collective effects of multiple genetic association signals on an AV-45 PET measure, which is a well-known Alzheimer's disease biomarker, by employing a network-assisted strategy. Methods: First, we took advantage of a dense module search algorithm to identify modules enriched by genetic association signals in a protein-protein interaction network. Next, we performed statistical evaluation to the modules identified by dense module search, including a normalization process to adjust the topological bias in the network, a replication test to ensure the modules were not found randomly , and a permutation test to evaluate unbiased associations between the modules and amyloid imaging phenotype. Finally, topological analysis, module similarity tests and functional enrichment analysis were performed for the identified modules. Results: We identified 24 consensus modules enriched by robust genetic signals in a genome-wide association analysis. The results not only validated several previously reported A1) genes (APOE, APP, TOMM40, DDAH1, PARK2, ATP5C1, PVRL2, ELAVL, ACTN1 and NRF1), but also nominated a few novel genes (ABL1, ABLIM2) that have not been studied in Alzheimer's disease but have shown associations with other neurodegenerative diseases. Conclusion: The identified genes, consensus modules and enriched pathways may provide important clues to future research on the neurobiology of Alzheimer's disease and suggest potential therapeutic targets.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据